Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

bioAffinity Technologies (BIAF) EBITDA: 2022-2025

Historic EBITDA for bioAffinity Technologies (BIAF) over the last 4 years, with Sep 2025 value amounting to -$2.2 million.

  • bioAffinity Technologies' EBITDA fell 16.29% to -$2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.2 million, marking a year-over-year decrease of 26.58%. This contributed to the annual value of -$8.8 million for FY2024, which is 13.58% down from last year.
  • According to the latest figures from Q3 2025, bioAffinity Technologies' EBITDA is -$2.2 million, which was up 9.02% from -$2.5 million recorded in Q2 2025.
  • In the past 5 years, bioAffinity Technologies' EBITDA ranged from a high of -$684,119 in Q2 2022 and a low of -$2.9 million during Q4 2024.
  • Over the past 3 years, bioAffinity Technologies' median EBITDA value was -$2.2 million (recorded in 2023), while the average stood at -$2.2 million.
  • As far as peak fluctuations go, bioAffinity Technologies' EBITDA slumped by 156.88% in 2023, and later climbed by 14.05% in 2024.
  • bioAffinity Technologies' EBITDA (Quarterly) stood at -$1.6 million in 2022, then slumped by 34.62% to -$2.2 million in 2023, then plummeted by 33.44% to -$2.9 million in 2024, then decreased by 16.29% to -$2.2 million in 2025.
  • Its EBITDA stands at -$2.2 million for Q3 2025, versus -$2.5 million for Q2 2025 and -$2.6 million for Q1 2025.